The first supportive care questionnaire application for patients receiving chemotherapy available in 5 languagesAn easy-to-use and easy-to-evaluate tool to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting
Lugano, Switzerland, March 5th, 2014 - (PressReleasePoint) -The MASCC Antiemesis Tool (MAT) is the first application for cancer patients receiving chemotherapy that assists healthcare professionals in evaluating if, and how much the anti-cancer treatment is causing nausea and vomiting.
Patients fighting cancer may experience chemotherapy-induced nausea and vomiting, potential side effects that may impact their quality of life. The MAT was developed by the Multinational Association for Supportive Care in Cancer, to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting that may occur with chemotherapy. The concept of the MAT is to provide an easy to use tool, that will assist in providing the best individual care for patients.
The MAT tool includes questions regarding the intensity and frequency of nausea and vomiting after chemotherapy; during the first 24 hours, and up to 4 days after chemotherapy.
After completing the MAT from a smartphone or a tablet, patients may send their responses to their physicians or nurses in real time.
Health care professionals can promptly follow up, and manage symptoms if necessary.
MAT is free and it is available in English, French, Italian, German and Spanish. The printable version of the questionnaire is available on the MASCC website (www.mascc.org) in English as well as in 11 languages: Arabic, French, German, Greek, Italian, Japanese, Korean, Portuguese, Serbian, Spanish, Turkish.
The MAT Tool is supported by an unrestricted grant form Helsinn Healthcare S.A..